These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37748124)

  • 1. Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial.
    Gillespie EF; Yang JC; Mathis NJ; Marine CB; White C; Zhang Z; Barker CA; Kotecha R; McIntosh A; Vaynrub M; Bartelstein MK; Mitchell A; Guttmann DM; Yerramilli D; Higginson DS; Yamada YJ; Kohutek ZA; Powell SN; Tsai J; Yang JT
    J Clin Oncol; 2024 Jan; 42(1):38-46. PubMed ID: 37748124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early palliative radiation versus observation for high-risk asymptomatic or minimally symptomatic bone metastases: study protocol for a randomized controlled trial.
    Rosen DB; Benjamin CD; Yang JC; Doyle C; Zhang Z; Barker CA; Vaynrub M; Yang TJ; Gillespie EF
    BMC Cancer; 2020 Nov; 20(1):1115. PubMed ID: 33203426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
    Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
    JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
    Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
    BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial.
    Rothrock RJ; Ozair A; Avendano MC; Herrera S; Appel H; Ramos S; Starosciak AK; Leon-Ariza DS; Rubens M; McDermott MW; Ahluwalia MS; Mehta MP; Kotecha RR
    Trials; 2024 Jan; 25(1):41. PubMed ID: 38217032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
    Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
    Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External beam radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs).
    Shulman RM; Meyer JE; Li T; Howell KJ
    Ann Palliat Med; 2019 Apr; 8(2):159-167. PubMed ID: 30525770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
    Hortobagyi GN; Van Poznak C; Harker WG; Gradishar WJ; Chew H; Dakhil SR; Haley BB; Sauter N; Mohanlal R; Zheng M; Lipton A
    JAMA Oncol; 2017 Jul; 3(7):906-912. PubMed ID: 28125763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
    Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
    Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial).
    Arrieta O; Maldonado F; Turcott JG; Zatarain-Barrón ZL; Barrón F; Blake-Cerda M; Cabrera-Miranda LA; Cardona AF; de la Garza JG; Rosell R
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1442-1450. PubMed ID: 33640422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
    Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
    Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
    Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ
    J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
    Lipton A; Fizazi K; Stopeck AT; Henry DH; Brown JE; Yardley DA; Richardson GE; Siena S; Maroto P; Clemens M; Bilynskyy B; Charu V; Beuzeboc P; Rader M; Viniegra M; Saad F; Ke C; Braun A; Jun S
    Eur J Cancer; 2012 Nov; 48(16):3082-92. PubMed ID: 22975218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
    Klaassen Z; Howard LE; de Hoedt A; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Cancer; 2017 May; 123(9):1528-1535. PubMed ID: 28026865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
    Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
    J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
    Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND;
    Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
    Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.